AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 80 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $40,000 | -60.4% | 17,202 | -19.3% | 0.00% | – |
Q4 2021 | $101,000 | -41.3% | 21,314 | -1.8% | 0.00% | – |
Q3 2021 | $172,000 | -55.8% | 21,698 | -61.2% | 0.00% | – |
Q2 2021 | $389,000 | -28.1% | 55,861 | -18.2% | 0.00% | -100.0% |
Q1 2021 | $541,000 | +0.7% | 68,275 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $537,000 | +19.6% | 68,275 | +7.8% | 0.00% | 0.0% |
Q3 2020 | $449,000 | -23.4% | 63,313 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $586,000 | +208.4% | 63,313 | +55.4% | 0.00% | – |
Q1 2020 | $190,000 | -38.3% | 40,749 | +1.2% | 0.00% | -100.0% |
Q4 2019 | $308,000 | -0.6% | 40,283 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $310,000 | +12.3% | 40,283 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $276,000 | +16.0% | 40,283 | +36.2% | 0.00% | – |
Q1 2019 | $238,000 | +23.3% | 29,576 | +14.7% | 0.00% | – |
Q4 2018 | $193,000 | -19.2% | 25,794 | +3.4% | 0.00% | – |
Q3 2018 | $239,000 | -9.5% | 24,949 | 0.0% | 0.00% | -100.0% |
Q2 2018 | $264,000 | – | 24,949 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |